Glioma-Derived Thrombospondin-1 Modulates Cd14+ Cell Tolerogenic Properties. (21st April 2015)

• Record Type: Journal Article
• Authors: Ma, Yuan; Qu, Bo; Xia, Xun; Yang, Libin; Kuang, Yongqin; Yang, Tao; Cheng, Jingmin; Sun, Haodong; Fan, Kexia; Gu, Jianwen
• Is Part Of: Cancer investigation. Volume 33:Number 4(2015)
• Page Start: 152
• Page End: 157
• Publication Date: 2015-04-21
• Subjects: Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.3109/07357907.2015.1010089
• Languages: English
• ISSNs: 0735-7907

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Thrombospondin-1 (TSP1) plays a role in the immune tolerance, and is involved in the pathogenesis of glioma. This study aims to investigate the role of the glioma-derived TSP1 in the induction of the tumor immune tolerance. The results showed that the primary human glioma cells expressed high levels of TSP1. Glioma cells enhanced the expression of transforming growth factor (TGF)-β in CD4⁺ CD16⁻ naïve monocytes (Mos). The TGF-β⁺ Mos showed inhibitory effect on CD8⁺ T cell proliferation. We conclude that glioma cell-derived TSP1 facilitates the induction of TGF-β in Mos. The TSP1 may be a potential therapeutic target of glioma.</p> </abstract>